ETX201 / Encoded Therap - LARVOL DELTA

Encoded Therapeutics Presents Promising New Data for CNS Gene Therapy Programs at the ASGCT 28th Annual Meeting (Businesswire) - "Encoded Therapeutics Inc...today announced the results of preclinical studies that underscore the strength of the Company’s vector engineering platform and demonstrate continued progress of programs for Angelman syndrome, Alzheimer’s disease / tauopathies and chronic pain. Three poster presentations are being highlighted at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in New Orleans, LA, May 13 – 17, 2025."

Preclinical • Genetic Disorders

Encoded Therapeutics Reports Clinical Progress of ETX101 Gene Therapy for Dravet Syndrome, Recaps 2024 Corporate Achievements and Provides 2025 Outlook (Businesswire) - "POLARIS program, launched in 2024 to evaluate ETX101 for SCN1A+ Dravet syndrome, is ongoing. Expect to complete dosing and share preliminary safety and efficacy data in 2H25...Following guidance from FDA, IND-enabling studies have been initiated to support a potential ETX201 IND filing in 2026...Data for both the pain and Alzheimer’s disease programs will be presented at scientific meetings in mid-2025."

IND • P1/2 data • Preclinical • Alzheimer's Disease • CNS Disorders • Pain